Interleukin-17 (IL-17) Plasma
Quantitative determination of circulating levels of human Interleukin-17 (IL-17) in serum and plasma have been reported in the scientific literature to be informative for understanding the host immunologic responses to infectious disease pathogens as well as certain cancerous tumors.1,2 In addition, determining quantitative levels of this proinflammatory cytokine may be beneficial in monitoring disease progression for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease and the acceptance or rejection of transplanted organ.1,3,5-7
Multiplex array format with Meso Scale Discovery (MSD®) Sector Imager 2400. MSD Cytokine assays measure from one to ten cytokines in a 96 well MULTI-SPOT plate. The assay employs a sandwich immunoassay format. MSD technology uses eletrochemiluminescence detection; a CDD camera allows for the quantification of light emitted from each spot in each well. MSD software generates a standard curve to determine sample cytokine concentrations. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Specific to IL-17 A.
3 business days from receipt of specimen.
|Specimen Type||Order Code||CPT Code||NY Approved||Volume||Assay Range||Special Instructions|
1 mL (min. 100 uL)
1.7 - 14000 pg/mL
The reference range for a healthy population is less than 2.2 pg/mL. However, it should be noted that these ranges are obtained from a limited population of apparently healthy adults and are not diagnostic thresholds.
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Viracor Eurofins test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Viracor Eurofins, 1001 NW Technology Dr, Lee's Summit, MO 64086
Invalid specimen type, inadequate volume, gross hemolysis or gross lipemia, sample not frozen upon receipt.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
1. Onishi RM, SL Gaffen. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunolgy. 2010 Mar;129(3):311-21.
2. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008 Jun;223:87–113.
3. Fabrega E, Lopez-Hoyos M, San Segundo D, Casafont F, Pons-Romero F. Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl. 2009 Jun;15(6):629-33.
4. Dander E, Balduzzi A, Zappa G, et al. Interleukin-17-producing T-Helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation. 2009 Dec 15;88(11):1261–72.
5. San Segundo D, Lopez-Hoyos M, Fernandez-Fresnedo G, et al. Th17 versus Treg cells in renal transplant candidates: effect of previous transplant. Transpl Proc. 2008 Nov;40(9):2885–8.
6. Kalinowska-Lyszczarz A, Szczucinski A, Pawlak MA, Losy J. Clinical study of CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing – remitting multiple sclerosis patients. J Neurol Sci. 2011 Jan 15;300(1-2):81-5. Epub 2010 Oct 13.
7. Marder W, Khalatbari S, Myles JD, et al. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis. 2011 Sep;70(9):1550-5.